The study team framed individualized therapy selection as a counterfactual inference problem. They developed a Structural Causal Model (SCM) that estimates individual treatment effects (ITE) for SGLT2 inhibitors using observational electronic health records. The SCM rests on an assumption the authors call counterfactual stability; that assumption permits mapping observed patient histories to plausible alternative outcomes under different treatment choices. The investigators implemented a Gumbel-Max sampling mechanism inside the causal model to capture stochastic elements of clinical treatment assignment. This choice allowed the model to represent randomness in prescribing behavior while retaining differentiable inference, enabling gradient-based optimization of treatment policies.
The authors described the SCM architecture and its counterfactual sampling as central to estimating patient-specific effects. Short statements in the abstract noted that the model operationalizes treatment assignment and outcome generation jointly. The manuscript abstract did not report granular model hyperparameters or the exact training regimen; those methodological details were not presented in the abstract and therefore cannot be restated here.
The study team defined an optimal treatment policy as the action that maximizes a counterfactual estimate of future diagnostic outcomes. In practice, that meant the SCM predicted the value—under a chosen utility specification—for each potential treatment, and selection favored the highest predicted counterfactual value. The authors evaluated the learned policy using a doubly robust value estimator. This estimator, according to the abstract, combines outcome modeling and propensity information to produce a value estimate that is less sensitive to misspecification of either component.
Investigators emphasized that policy evaluation compared model-derived recommendations with actual, real-world prescriptions recorded in the EHR. The abstract reports that the Counterfactual Gumbel-Max SCM produced higher predicted treatment value across diagnostic categories than existing prescribing patterns, implying potential opportunity to refine individualized treatment decisions. The abstract did not detail the exact diagnostic outcomes used as the value targets or provide numerical performance metrics; those specifics were not included in the available text.
Data indicated that when policies derived from the SCM were compared to observed clinician choices, the model’s recommendations achieved greater predicted counterfactual value. The study team reported that this improvement was observed across diagnostic categories and that the framework identified subpopulations with larger predicted benefits from SGLT2 inhibitors. This signals heterogeneous treatment effects: some patients appear to gain more from SGLT2 inhibitor therapy than others, according to the model.
The abstract does not list which clinical subgroups—by age, comorbidity profile, baseline kidney function, or other covariates—showed the largest gains. The authors therefore did not provide subgroup effect sizes or selection rules in the abstract. Any clinician or data scientist reading this summary should note that subgroup definitions and effect magnitudes require consultation of the full manuscript or direct communication with the authors.
The analysis used anonymized clinical records collected as part of routine care between 2000 and 2021. The authors stated the work is retrospective and did not involve experimental interventions. Ethics approvals were obtained from the Scientific and Research Ethics Committee of the Hungarian Medical Research Council (TUKEB; approval number 44549-2/2018/EKU) and from the Regional and Institutional Research Ethics Committee of the University of Debrecen (DE RKEB/IKEB; approval number 6697-2024). Both committees waived informed consent in accordance with applicable national legislation and institutional rules because the dataset consisted of anonymized records.
The preprint indicates the datasets are not publicly available due to terms of those ethical approvals. The authors wrote that data may be available from the corresponding author on reasonable request; the abstract includes no further data-sharing workflow or code-release timeline. Readers interested in replication or secondary analyses should contact the corresponding author for access details.
This report is a medRxiv preprint and has not undergone peer review; the authors themselves stated the manuscript should not be used to guide clinical practice. The abstract did not include sample sizes, cohort demographics, outcome definitions, model hyperparameters, or full sensitivity analyses. Those methodological and reporting gaps mean the claims about outperforming real-world prescriptions rest on analyses detailed in the full paper rather than the abstract alone.
The SCM depends on counterfactual assumptions—counterfactual stability and correct specification of the causal graph—that cannot be validated from observational records alone. The abstract did not describe robustness checks for unmeasured confounding or how missing data were handled. External validation in independent datasets was not mentioned in the abstract, and therefore remains an open question. Finally, because the underlying datasets cannot be shared publicly without approval, independent replication requires negotiation with the authors and adherence to the stated ethical constraints.
Readers should view these findings as a computational proof of concept: investigators reported a modeling framework that integrates causal inference and EHR data to produce individualized treatment policies for SGLT2 inhibitors, but regulatory, validation, and clinical-implementation steps remain. The next concrete steps documented in the abstract are limited to data-access provision by the corresponding author and the standard peer-review process; no regulatory milestones or implementation timelines were provided in the abstract.